By
Kashyap Raibagi
Published: Feb. 24, 2019, 9:20 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Access
Mumbai: Drug-resistant tuberculosis (DR-TB) patients in India face delayed diagnoses, different treatment pathways from both public and private health care systems and differing costs for the same treatments from different providers in an unregulated private health care sector, says a January 2019 study published in Public Library of Science (PLOS), a scientific journal.
Read More →
